Rescuing the traffic-deficient mutants of rat μ-opioid receptors with hydrophobic ligands

Molecular Pharmacology

Volumn 64, Issue 1, 2003, Pages 32-41

  Chaipatikul, Vipa ^a   Erickson Herbrandson, Laurie J ^a   Loh, Horace H ^a   Law, Ping Yee ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ETORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE;

ARTICLE; CELL LINE; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE TRANSPORT; CELL SURFACE; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TIME;

ANIMALS; CELLS, CULTURED; CYCLIC AMP; ETORPHINE; HUMANS; LIGANDS; MEMBRANE PROTEINS; MUTATION; NALOXONE; NARCOTICS; RATS; RECEPTORS, OPIOID, MU; TRANSFECTION;

EID: 0037561587     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.1.32     Document Type: Article

References (37)

1. Bradbury FA, Kawate N, Foster CM, and Menon KM (1997) Post-translational processing in the Golgi plays a critical role in the trafficking of the luteinizing hormone/human chorionic gonadotropin receptor to the cell surface. J Biol Chem 272:5921-5926.
2. Chen CA and Okayama H (1988) Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 6:632-638.
3. Cheung AH, Huang RR, and Strader CD (1992) Involvement of specific hydrophobic, but not hydrophilic, amino acids in the third intracellular loop of the beta-adrenergic receptor in the activation of Gs. Mol Pharmacol 41:1061-1065.
4. Chicchi GG, Graziano MP, Koch G, Hey P, Sullivan K, Vicario PP, and Cascieri MA (1997) Alterations in receptor activation and divalent cation activation of agonist binding by deletion of intracellular domains of the glucagon receptor. J Biol Chem 272:7765-7769.
5. Couvineau A, Fabre C, Gaudin P, Maoret JJ, and Laburthe M (1996) Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry 35:1745-1752.
6. Georgoussi Z, Merkouris M, Mullaney I, Megaritls G, Carr C, Zioudrou C, and Milligan G (1997) Selective interactions of mu-opioid receptors with pertussis toxin-sensitive G proteins: involvement of the third intracellular loop and the c-terminal tail in coupling. Biochim Biophys Acta 1359:263-274.
7. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, and Kobilka BK (1997) Structural Instability of a constitutively active g protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590.
8. Halaban R, Svedine S, Cheng E, Smicun Y, Aron R, and Hebert DN (2000) Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism Proc Natl Acad Sci U S A 97:5889-5894.
9. Heinflink M, Nussenzveig DR, Grimberg H, Lupu-Meiri M, Oron Y, and Gershengorn MC (1995) A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist. Mol Endocrino 9:1455-1460.
10. Huang P, Li J, Chen C, Visiers I, Weinstein H, and Liu-Chen LY (2001) Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry 40:13501-13509.
11. Krause G, Hermosilla R, Oksche A, Rutz C, Rosenthal W, and Schulein R (2000) Molecular and conformational features of a transport-relevant domain in the C-terminal tail of the vasopressin V2 receptor. Mol Pharmacol 57:232-242.
12. Law PY, Wong YH, and Loh HH (1999) Mutational analysis of the structure and function ofopioid receptors. Biopolymers 51:440-455.
13. Law PY, Erickson LJ, El-Kouhen R, Dicker L, Solberg J, Wang W, Miller E, Burd AL, and Loh HH (2000) Receptor density and recycling affect the rate of agonist-induced desensitization of μ-opioid receptor. Mol Pharmacol 58:388-398.
14. Le A, Steiner JL, Ferrell GA, Shaker JC, and Sifers RN (1994) Association between calnexin and a secretion-incompetent variant of human α1-antitrypsin. J Biol Chem 269:7514-7519.
15. Li J, Huang P, Chen C, de Riel JK, Weinstein H, and Liu-Chen LY (2001) Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression. Biochemistry 40:12039-12050.
16. Loo TW and Clarke DM (1994) Prolonged association of temperature-sensitive mutants of human P-glycopretein with calnexin during biogenesis. J Biol Chem 269:28683-28689.
17. MacEwan DJ and Milligan G (1996) Inverse agonist-induced up-regulation of the human β2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol Pharmacol 50:1479-1486.
18. McLean AJ, Bevan N, Rees S, and Milligan G (1999) Visualizing differences in ligand regulation of wild-type and constitutively active mutant β2-adrenoceptor-green fluorescent protein fusion proteins. Mol Pharmacol 56:1182-1191.
19. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG, et al. (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105:887-895.
20. Oksche A, Dehe M, Schulein R, Wiesner B, and Rosenthal W (1998) Folding and cell surface expression of the vasopressin V2 receptor: requirement of the intracellular C terminus. FEBS Lett 424:57-62.
21. Pei G, Samama P, Lohse M, Wang M, Codina J, and Lefkowitz RJ (1994) A Constitutively active mutant β2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc Natl Acad Sci U S A 91:2699-2702.
22. Petaja-Repo UE, Hogue M, Laperriere A, Walker P and Bouvier (2000) Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human opioid receptor. J Biol Chem 275:13727-13736.
23. Petaja-Repo UE, Hogue M, Bhalla S, Laperriere A, Morello JP, and Bouvier M (2002) Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO (Eur Mol Biol Organ) J 21:1628-1637.
24. Pind S, Riordan JR, and Williams DB (1994) Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 269:12784-12788.
25. Ray K, Fan GF, Goldsmith PK, and Spiegel AM (1997) The carboxyl terminus of the human calcium receptor. Requirements for cell-surface expression and signal transduction. J Biol Chem 272:31355-31361.
26. Rozzell TG, Wang H, Liu X, and Segaloff DL (1995) Intracellular retention of mutant gonadotropin receptors results in loss of hormone binding activity of the follitropin receptor but not of the lutropin/choriogonadotropin receptor. Mol Endocrino 9:1727-1736.
27. Rozell TG, Davis DP, Chai Y, and Segaloff DL (1998) Association of gonadotropin receptor precursors with the protein folding chaperone calnexin. Endocrinology 139:1588-1593.
28. Samama P, Bond RA, Rockman HA, Milano CA, and Lefkowitz RJ (1997) Ligand-induced overexpression of a constitutively active β2-adrenergic receptor: Pharmacological creation of a phenotype in transgenic mice. Proc Natl Acad Sci USA 94:137-141.
29. Schulein R, Hermosilla R, Oksche A, Dehe M, Wiesner B, Krause G, and Rosenthal W (1998) A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS M6 cells. Mol Pharmacol 54:525-535.
30. Smirnov D, Usachev YM, Law PY, and Loh HH (2002) Role of the delta opioid receptor carboxyl tail in receptor translocation. Program No. 515.1. 2002 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington DC. Online.
31. Stevens PA, Bevan N, Rees S, and Milligan G (2000) Resolution of inverse agonist-induced up-regulation from constitutive activity of mutants of the α1b-adrenoceptor. Mol Pharmacol 58:438-448.
32. Unson CG, Cypess AM, Kim HN, Goldsmith PK, Carruthers CJ, Merrifield RB, and Sakmar TP (1995) Characterization of deletion and truncation mutants of the rat glucagon receptor. J Biol Chem 270:27720-27727.
33. Wess J (1998) Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 80:231-264.
34. Williams AM and Enns CA (1993) A region of the C-terminal portion of the human transferrin receptor contains an asparagine-linked glycosylation site critical for receptor structure and function J Biol Chem 268:12780-12786.
35. Wonerow P, Schoneberg T, Schultz G, Gudermann T, and Paschke R (1998) Deletions in the third intracellular loop of the thyrotropin receptor. A new mechanism for constitutive activation. J Biol Chem 273:7900-7905.
36. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, and Perlmutter DH (1994) A lag in intracellular degradation of mutant α1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ α1-antitrypsin deficiency. Proc Natl Acad Sci USA 91:9014-9018.
37. Yang Y, Janich S, Cohn JA, and Wilson JM (1993) The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci USA 90:9480-9484.